Prothena (NASDAQ:PRTA) Shares Break Below Two Hundred Day Moving Average – What’s Next?Defense World · 1 day ago
Prothena's Partnership Strategy: Growth Driver or Limitation?Zacks Investment Research · 4 days ago
Prothena Corporation plc (NASDAQ:PRTA) Stock Has Average Price Target of $24.57Defense World · Oct 13, 2026
Prothena (NASDAQ:PRTA) Stock: Insider William Scully Acquires 125,000 SharesDefense World · Oct 11, 2026
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?Zacks Investment Research · Oct 8, 2026
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's DayZacks Investment Research · Sep 21, 2026Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.39 | -$0.32 | Beat |
| May 7, 2026 | -$0.31 | $0.60 | Beat |
| Feb 19, 2026 | -$0.45 | -$0.44 | Beat |
| Nov 6, 2025 | -$0.60 | -$0.67 | Miss |
| Aug 4, 2025 | -$1.11 | -$1.86 | Miss |
| May 8, 2025 | -$0.92 | -$1.12 | Miss |